First generation

Pixelmon Brings Fully Decentralized Monster IP Vision to Immutable

Retrieved on: 
Monday, February 12, 2024

SYDNEY, Feb. 12, 2024 /PRNewswire/ -- Immutable, the leading web3 gaming platform and ecosystem, today announced a partnership with LiquidX, the studio behind revitalized battle arena game Pixelmon, which is set to launch on the recently released Immutable zkEVM. The LiquidX team aims to build the world's first truly decentralized intellectual property (IP) for monster capture and combat, beginning with a four-part relaunch roadmap.

Key Points: 
  • The LiquidX team aims to build the world's first truly decentralized intellectual property (IP) for monster capture and combat, beginning with a four-part relaunch roadmap.
  • As the second-highest gaming NFT by transaction volume on OpenSea, anticipation for Pixelmon remains high amongst web3 gamers.
  • Under new leadership from LiquidX co-founder Giulio Xiloyannis, Pixelmon is gearing up to deliver a fast-paced monster combat experience.
  • This will lead to an open-world RPG launch and ultimately, a fully decentralized multiplayer metaverse owned by the Pixelmon community.

Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Tuesday, December 19, 2023

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2023.
  • Know Labs reported a net loss of $15.29 million dollars in FY2023, compared to a net loss of $20.07 million dollars in FY2022, a reduction in net loss of 23.8%.
  • Net cash used in operations for FY2023 was $10.35 million dollars compared with $6.92 million in the prior year.
  • Shareholder equity for the fiscal year 2023 was $3.74 million versus $9.86 million in fiscal year 2022.

Biomethane Market worth $60.2 Billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, November 23, 2023

The power generation segment is set to dominate the biomethane market, securing the largest market share.

Key Points: 
  • The power generation segment is set to dominate the biomethane market, securing the largest market share.
  • This prominence is driven by the growing recognition of biomethane as a clean and sustainable energy source for electricity production.
  • Municipal waste is anticipated to claim the highest market share in the biomethane market.
  • Europe is poised to command the largest market share in the biomethane market, primarily due to the region's proactive approach towards renewable energy and stringent environmental regulations.

Biomethane Market worth $60.2 Billion by 2030 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, November 23, 2023

The power generation segment is set to dominate the biomethane market, securing the largest market share.

Key Points: 
  • The power generation segment is set to dominate the biomethane market, securing the largest market share.
  • This prominence is driven by the growing recognition of biomethane as a clean and sustainable energy source for electricity production.
  • Municipal waste is anticipated to claim the highest market share in the biomethane market.
  • Europe is poised to command the largest market share in the biomethane market, primarily due to the region's proactive approach towards renewable energy and stringent environmental regulations.

Global Anti-Epileptic Drugs (AEDs) Market Set to Reach $11.47 Billion by 2028 with a Steady 3.39% CAGR, Fueled by Improved Effectiveness and Patient Compliance - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023

This growth is attributed to the increasing effectiveness of AEDs in controlling seizures, accompanied by fewer side effects, resulting in improved patient compliance.

Key Points: 
  • This growth is attributed to the increasing effectiveness of AEDs in controlling seizures, accompanied by fewer side effects, resulting in improved patient compliance.
  • Anti-Epileptic Drugs (AEDs) have evolved significantly in recent years, becoming central in addressing various epilepsy-related syndromes and offering tailored care for patients.
  • By Drug Generation: The global AEDs market is segmented into First Generation, Second Generation, and Third Generation.
  • Post-pandemic, the anti-epileptic drugs market landscape underscores the need for enhanced supply chain resilience and integrated digital healthcare.

Unicoin to Be Listed on LBank Exchange, a Leading Global Digital Asset Trading Platform

Retrieved on: 
Tuesday, October 10, 2023

This collaboration signifies our commitment to innovation and our dedication to providing our users with cutting-edge cryptocurrency options," said Peter Fang, Listing Director of LBank Exchange.

Key Points: 
  • This collaboration signifies our commitment to innovation and our dedication to providing our users with cutting-edge cryptocurrency options," said Peter Fang, Listing Director of LBank Exchange.
  • "We're thrilled to list Unicoin on LBank Exchange, one of the world's leading crypto exchanges with a strong track record of security and reliability," said Alex Konanykhin, CEO of Unicoin.
  • The date of listing of Unicoin on LBank Exchange will be announced separately and be selected based on the dynamics of the crypto market.
  • Unicoin is expected to be listed on major crypto exchanges by the end of 2023.

Know Labs, Inc. Reports Third Quarter FY2023 Results

Retrieved on: 
Monday, August 14, 2023

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023.
  • Research and development expense for the third quarter was $1.87 million dollars as compared to $1.27 million dollars in 2022.
  • As we have stated in our Third Quarter 10-Q, during 2023, we expect to raise additional funds through the issuance of preferred stock, convertible debentures, and equity.
  • Shareholder equity for the third quarter 2023 was $0.72 million versus $9.9 million as of September 30, 2022.

Denny's Partners with Houston Leaders for a Sports-Filled Week of Giving Back

Retrieved on: 
Saturday, July 29, 2023

HOUSTON, July 28, 2023 /PRNewswire/ -- Denny's has joined forces with two Houston-based organizations to give back to the community.

Key Points: 
  • HOUSTON, July 28, 2023 /PRNewswire/ -- Denny's has joined forces with two Houston-based organizations to give back to the community.
  • Sister 2 Sistah is a Houston-based organization on a mission to help college-aged women of color from across the country.
  • The event will provide the opportunity for 100 children from underserved communities in Houston to attend a free Astros game.
  • Approximately 75 children will attend this basketball camp and workshop, which is open to Houston-area students from Pre-K– Grade 12.

Generative AI Will Power a New HR Talent Intelligence Paradigm, The Josh Bersin Company Predicts

Retrieved on: 
Thursday, July 13, 2023

OAKLAND, Calif., July 13, 2023 /PRNewswire/ -- The Josh Bersin Company, the world's most trusted global human capital advisory firm, has today announced new research findings highlighting the huge potential of ChatGPT-style "Generative AI" to help companies sharpen their hiring and development practices—but only if organizations dispel their fear of the technology.

Key Points: 
  • The Josh Bersin Company interviewed senior AI-aware execs, engineers, and product leaders, about Generative AI's potential to create powerful new insights for HR leaders and Learning and Development teams.
  • Additionally, the research also defines three categories of AI solutions: Emerging (AI added on), First Generation (where the AI is built in), and Second Generation (where the solution is built on AI).
  • "Using Generative AI to understand the subtler but more transformative learnings from recruitment and talent data is also just the first step in an exciting ongoing tech and data-based HR AI journey.
  • The Josh Bersin Company previewed its own AI solution, The HR Copilot, at its June Irresistible 2023 event.

Acerus Update

Retrieved on: 
Tuesday, July 11, 2023

TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) and its previously announced sale and investment solicitation process (the “SISP”), the Company completed the previously announced transactions (the “Transaction”) with First Generation Capital Inc. (“First Generation”) as successful bidder under the SISP.

Key Points: 
  • TORONTO, July 10, 2023 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (the “Company”) announces that, in connection with its creditor protection proceedings under the Companies’ Creditors Arrangement Act (the “CCAA”) and its previously announced sale and investment solicitation process (the “SISP”), the Company completed the previously announced transactions (the “Transaction”) with First Generation Capital Inc. (“First Generation”) as successful bidder under the SISP.
  • The Transaction was approved by the Ontario Superior Court of Justice (Commercial List) (the “Court”) on May 30, 2023 (the “Approval Order”).
  • Following completion of the Transaction, in accordance with the definitive agreement in respect of the Transaction and the Approval Order, all of the previously issued and outstanding common shares of the Company have been cancelled without consideration and the Company became a wholly-owned subsidiary of First Generation.
  • Copies of the orders granted by the Court, as well as other information regarding the CCAA proceedings, are available on the Monitor’s website at www.ey.com/ca/acerus .